Other formats:
BibTeX
LaTeX
RIS
@article{806137,
author = {Rawstron, AC and Orfao, A and Beksac, M and Bezdickova, L and Brooimans, RA and Bumbea, H and Dalva, K and Fuhler, D and Gratama, J and Hose, D and Kovarova, L and Johnsen, HE},
article_location = {Pavia},
article_number = {3},
keywords = {flow cytometry; myeloma; MGUS},
language = {eng},
issn = {0390-6078},
journal = {Haematologica/the hematology journal},
title = {Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders},
url = {http://www.haematologica.org/cgi/reprint/93/3/431},
volume = {93},
year = {2008}
}
TY - JOUR
ID - 806137
AU - Rawstron, AC - Orfao, A - Beksac, M - Bezdickova, L - Brooimans, RA - Bumbea, H - Dalva, K - Fuhler, D - Gratama, J - Hose, D - Kovarova, L - Johnsen, HE
PY - 2008
TI - Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
JF - Haematologica/the hematology journal
VL - 93
IS - 3
SP - 431-438
EP - 431-438
PB - Ferrata Storti Foundation
SN - 03906078
KW - flow cytometry
KW - myeloma
KW - MGUS
UR - http://www.haematologica.org/cgi/reprint/93/3/431
N2 - The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice in participating laboratories. The second aimed to resolve outstanding technical issues and develop a consensus approach to analysis of plasma cells. The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease. A range of technical recommendations were identified, including: 1) CD38, CD138 and CD45 should all be included in at least one tube for plasma cell identification and enumeration. The primary gate should be based on CD38 vs. CD138 expression; 2) after treatment, clonality assessment is only likely to be informative when combined with immunophenotype to detect abnormal cells. Flow cytometry is suitable for demonstrating a stringent complete remission; 3) for detection of abnormal plasma cells, a minimal panel should include CD19 and CD56. A preferred panel would also include CD20, CD117, CD28 and CD27; 4) discrepancies between the percentage of plasma cells detected by flow cytometry and morphology are primarily related to sample quality and it is, therefore, important to determine that marrow elements are present in follow-up samples, particularly normal plasma cells in MRD negative cases.
ER -
RAWSTRON, AC, A ORFAO, M BEKSAC, L BEZDICKOVA, RA BROOIMANS, H BUMBEA, K DALVA, D FUHLER, J GRATAMA, D HOSE, L KOVAROVA and HE JOHNSEN. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Online. \textit{Haematologica/the hematology journal}. Pavia: Ferrata Storti Foundation, 2008, vol.~93, No~3, p.~431-438. ISSN~0390-6078. [citováno 2024-04-24]
|
